keyword
MENU ▼
Read by QxMD icon Read
search

spasticity botulinum toxin

keyword
https://www.readbyqxmd.com/read/29423615/defining-spasticity-a-new-approach-considering-current-movement-disorders-terminology-and-botulinum-toxin-therapy
#1
Dirk Dressler, Roongroj Bhidayasiri, Saeed Bohlega, Pedro Chana, Hsin Fen Chien, Tae Mo Chung, Carlo Colosimo, Markus Ebke, Klemens Fedoroff, Bernd Frank, Ryuji Kaji, Petr Kanovsky, Serdar Koçer, Federico Micheli, Olga Orlova, Sebastian Paus, Zvezdan Pirtosek, Maja Relja, Raymond L Rosales, José Alberto Sagástegui-Rodríguez, Paul W Schoenle, Gholam Ali Shahidi, Sofia Timerbaeva, Uwe Walter, Fereshte Adib Saberi
Spasticity is a symptom occurring in many neurological conditions including stroke, multiple sclerosis, hypoxic brain damage, traumatic brain injury, tumours and heredodegenerative diseases. It affects large numbers of patients and may cause major disability. So far, spasticity has merely been described as part of the upper motor neurone syndrome or defined in a narrowed neurophysiological sense. This consensus organised by IAB-Interdisciplinary Working Group Movement Disorders wants to provide a brief and practical new definition of spasticity-for the first time-based on its various forms of muscle hyperactivity as described in the current movement disorders terminology...
February 8, 2018: Journal of Neurology
https://www.readbyqxmd.com/read/29422486/evaluating-the-functional-outcomes-of-ultrasound-guided-botulinum-toxin-type-a-injections-using-the-euro-musculus-approach-for-upper-limb-spasticity-treatment-in-post-stroke-patients-an-observational-study
#2
Raikan Buyukavci, Semra Akturk, Yüksel Ersoy
BACKGROUND: Ultrasound-guided botulinum toxin type A injection is an effective treatment for spasticity. Euro-musculus spasticity approach is a new method for administering injections to the correct point of the correct muscle. The clinical outcomes of this practical approach is not yet available in the literature. AIM: The purpose of this study was to evaluate the effects on spasticity and the functional outcomes of ultrasound guided botulinum toxin type A injections via the Euro-musculus spasticity approach to treat upper limb spasticity in post-stroke patients...
February 7, 2018: European Journal of Physical and Rehabilitation Medicine
https://www.readbyqxmd.com/read/29408357/evidence-on-botulinum-toxin-in-selected-disorders
#3
Simpson, Elina Zakin
Botulinum toxin (BoNT) is a neurotoxin produced by the bacteria Clostridium botulinum that has become widely used for various neurologic indications. The four toxin formulations currently available for use in the United States (approved by the Food and Drug Administration) are onabotulinumtoxinA (Botox®), abobotulinumtoxinA (Dysport®), incobotulinumtoxinA (Xeomin®), and rimabotulinumtoxinB (Myobloc®). While the FDA-approved labels indicate that potency conversions should not be done, literature supports relative dose equivalents of approximately 1:1:2-4:50-100, respectively...
February 3, 2018: Toxicon: Official Journal of the International Society on Toxinology
https://www.readbyqxmd.com/read/29383493/treatment-with-botulinum-toxin-for-refractory-fever-caused-by-severe-spasticity-a-case-series
#4
Jacobo Lester, Gerardo Esteban Alvarez-Resendiz, Enrique Klériga, Fernando Videgaray, Gerardo Zambito
INTRODUCTION: Brain and spinal cord injuries may cause very severe spasticity that occasionally may be associated with persistent fever. CASE SERIES: We present 14 patients with spasticity and persistent fever, treated with botulinum toxin type A. Their spasticity improved and the fever resolved within a period no greater than 48 h. In all cases, infectious and other non-infectious causes were ruled out. CONCLUSIONS: When sustained tonic muscular activity is associated with a significant increase in body temperature and is refractory to the usual drugs used for hyperpyrexia, type A botulinum toxin may be an effective treatment option to control both spasticity and fever...
January 30, 2018: Neurology and Therapy
https://www.readbyqxmd.com/read/29380788/reactivation-of-herpes-simplex-viral-keratitis-following-the-botulinum-toxin-injection
#5
Muralidhar Ramappa, Peter Y Jiya, Sunita Chaurasia, Milind Naik, Savitri Sharma
We describe a case of 55-year-old male farmer presented with recurrent corneal abrasions with a spastic entropion in the left eye. Superior cornea showed typical nummular opacities suggestive resolved herpetic eye diseases. On further enquiry, he had similar episodes in the past. Contralateral eye was essentially normal. Following the botulinum toxin injection for the management of spastic entropion, subject developed reactivation of herpetic necrotizing stromal keratitis. Diagnostic corneal scrapings were negative for herpes simplex virus-1 antigen by immunofluorescence assay and for DNA by molecular techniques...
February 2018: Indian Journal of Ophthalmology
https://www.readbyqxmd.com/read/29339959/medical-cannabis-a-beneficial-high-in-treatment-of-blepharospasm-an-early-observation
#6
Phillip M Radke, Ali Mokhtarzadeh, Michael S Lee, Andrew R Harrison
The objective of this study was to observe the effect of medical cannabis in benign essential blepharospasm (BEB) as an adjunct to botulinum toxin. A retrospective chart review was performed on patients certified for medical cannabis use for BEB from September 2015 to May 2016. Patient demographics and responses, cannabis history, and severity indices were collected. Ten patients were certified for medical cannabis use. Five met the inclusion criteria, which was any patient with a diagnosis of BEB receiving standard botulinum toxin treatment who had started medical cannabis treatment by a registered distributor within the state, and was contactable by phone...
October 2017: Neuro-ophthalmology
https://www.readbyqxmd.com/read/29322885/analysis-of-a-15-years-experience-in-including-shoulder-muscles-when-treating-upper-limb-spasticity-post-stroke-with-botulinum-toxin-type-a
#7
Maria Pais de Carvalho, Daniela Pinto, Melissa Gorayeb, Jorge Jacinto
Background Botulinum toxin type-A (BoNTA) is a recognized treatment for upper limb spasticity (ULS) after stroke, but there aren't many studies analyzing its effect in shoulder muscles. Objective To evaluate the efficacy of BoNTA injections for ULS, when shoulder muscles are included. Methods A cross-sectional study. Data from clinical forms of outpatients, treated at a Rehabilitation Center (2001-2016). Analyzes: goals of treatment; demographic characteristics/goal; treatment success, using Goal Attainment Scaling...
January 11, 2018: Topics in Stroke Rehabilitation
https://www.readbyqxmd.com/read/29304876/a-systematic-review-efficacy-of-botulinum-toxin-in-walking-and-quality-of-life-in-post-stroke-lower-limb-spasticity
#8
Anupam Datta Gupta, Wing Hong Chu, Stuart Howell, Subhojit Chakraborty, Simon Koblar, Renuka Visvanathan, Ian Cameron, David Wilson
BACKGROUND: Improved walking is one of the highest priorities in people living with stroke. Post-stroke lower limb spasticity (PSLLS) impedes walking and quality of life (QOL). The understanding of the evidence of improved walking and QOL following botulinum toxin (BoNTA) injection is not clear. We performed a systematic review of the randomized control trials (RCT) to evaluate the effectiveness of BoNTA injection on walking and QOL in PSLLS. METHODS: We searched PubMed, Web of Science, Embase, CINAHL, ProQuest Thesis and Dissertation checks, Google Scholar, WHO International Clinical Trial Registry Platform, ClinicalTrials...
January 5, 2018: Systematic Reviews
https://www.readbyqxmd.com/read/29301539/development-of-an-inventory-of-goals-using-the-international-classification-of-functioning-disability-and-health-in-a-population-of-non-ambulatory-children-and-adolescents-with-cerebral-palsy-treated-with-botulinum-toxin-a
#9
Linda Nguyen, Ronit Mesterman, Jan Willem Gorter
BACKGROUND: In the management of hypertonicity in children with cerebral palsy (CP), goals should be clearly identified in order to evaluate the effectiveness of botulinum toxin A (BoNT-A) treatment, specifically in non-ambulatory children and adolescents, Gross Motor Function Classification System (GMFCS), level IV or V. A retrospective chart review (Mesterman et al., 2013) identified the need for the development of a set of specific and meaningful goals linked to the International Classification of Functioning, Disability and Health (ICF) for future goal setting and evaluation in this population...
January 4, 2018: BMC Pediatrics
https://www.readbyqxmd.com/read/29228927/treatment-with-botulinum-toxin-a-in-a-total-population-of-children-with-cerebral-palsy-a-retrospective-cohort-registry-study
#10
Maria Franzén, Gunnar Hägglund, Ann Alriksson-Schmidt
BACKGROUND: Botulinum toxin A (BTX-A) has been used to reduce spasticity in children with cerebral palsy (CP) for decades. The purpose of this study was to analyze to what extent BTX-A treatment was used to treat spasticity in a total population of children with CP. We investigated 1) the use of BTX-A in relation to age, sex, and Gross Motor Function Classification System (GMFCS) level, 2) the most common muscle groups treated with BTX-A in relation to the same variables, and 3) changes in the proportions of children treated with BTX-A between two time points (2010 and 2015)...
December 11, 2017: BMC Musculoskeletal Disorders
https://www.readbyqxmd.com/read/29185676/effect-of-physiotherapeutic-intervention-on-the-gait-after-the-application-of-botulinum-toxin-in-children-with-cerebral-palsy-systematic-review
#11
Paulo R Fonseca, Renata C Franco de Moura, Manuela Galli, Claudia Santos Oliveira
BACKGROUND: Cerebral palsy is a group of movement and posture development disorders. 90% of this population has gait impairment, often due to the presence of spasticity. A number of studies emphasize the importance of combined physical therapy with botulinum toxin A treatment. However, no consensus can be reached concerning the content of the physiotherapy programme after treatment with botulinum toxin A. AIM: The purpose of the present study was to investigate, through a systematic review of the literature, the effects of physiotherapeutic intervention on gait after botulinum toxin application in children with cerebral palsy...
November 29, 2017: European Journal of Physical and Rehabilitation Medicine
https://www.readbyqxmd.com/read/29171499/-treatment-of-spasticity-after-traumatic-brain-injury-in-children-the-role-of-botulinum-toxin-therapy
#12
O A Klochkova, A L Kurenkov, N A Mamontova
Traumatic brain injury (TBI) is one of the main reasons of death and disability in children and adolescents in Russia and abroad. Spasticity is a frequent outcome of the TBI that influences on the rehabilitation prognosis, degree of movement disorders and quality of life after trauma. Early spasticity correction and complex rehabilitation lead to the optimal recovery and prevent secondary complications. This review presents the current data about the prognostic role of the spasticity in children after TBI, methods of its correction and their scientific evidence...
2017: Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova
https://www.readbyqxmd.com/read/29165784/interventions-for-managing-skeletal-muscle-spasticity-following-traumatic-brain-injury
#13
REVIEW
Anneliese Synnot, Marisa Chau, Veronica Pitt, Denise O'Connor, Russell L Gruen, Jason Wasiak, Ornella Clavisi, Loyal Pattuwage, Kate Phillips
BACKGROUND: Skeletal muscle spasticity is a major physical complication resulting from traumatic brain injury (TBI), which can lead to muscle contracture, joint stiffness, reduced range of movement, broken skin and pain. Treatments for spasticity include a range of pharmacological and non-pharmacological interventions, often used in combination. Management of spasticity following TBI varies from other clinical populations because of the added complexity of behavioural and cognitive issues associated with TBI...
November 22, 2017: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/29156545/ultrasonographic-evaluation-of-botulinum-toxin-injection-site-for-the-medial-approach-to-tibialis-posterior-muscle-in-chronic-stroke-patients-with-spastic-equinovarus-foot-an-observational-study
#14
Alessandro Picelli, Alessio Baricich, Elena Chemello, Nicola Smania, Carlo Cisari, Marialuisa Gandolfi, Nicoletta Cinone, Maurizio Ranieri, Andrea Santamato
The tibialis posterior muscle is a frequent target for injection of botulinum toxin during the management of spastic equinovarus foot in adults with post-stroke spasticity. Although it is deep-seated, the needle insertion into the tibialis posterior muscle is usually performed using anatomical landmarks and safety information obtained from healthy subjects and cadavers. Our aim was to evaluate the botulinum toxin injection site for the medial approach to the tibialis posterior muscle in chronic stroke patients with spastic equinovarus foot...
November 18, 2017: Toxins
https://www.readbyqxmd.com/read/29150297/prolonged-stretching-of-the-ankle-plantarflexors-elicits-muscle-tendon-adaptations-relevant-to-ankle-gait-kinetics-in-children-with-spastic-cerebral-palsy
#15
Teresa Martín Lorenzo, Eduardo Rocon, Ignacio Martínez Caballero, Ana Ramírez Barragán, Sergio Lerma Lara
Tissue related ankle hyper-resistance has been reported to contribute to equinus gait in children with spastic cerebral palsy. Hence, ankle plantarflexor stretching programs have been developed in order to restore passive ankle dorsiflexion. Despite high quality evidence on the limited effects of stretching on passive joint mobility, further muscle-tendon adaptations have been reported which may impact gait performance. As such, children with spastic cerebral palsy subject to long-term manual static stretching achieved dorsiflexion gains through the reduction of muscle and fascicle strain whilst preserving tendon strain, and prolonged use of ankle-foot orthoses achieved similar dorsiflexion gains through increased tendon strain whilst preserving muscle and fascicle strain...
November 2017: Medical Hypotheses
https://www.readbyqxmd.com/read/29146092/ultrasonographic-evaluation-of-changes-in-the-muscle-architecture-of-the-gastrocnemius-with-botulinum-toxin-treatment-for-lower-extremity-spasticity-in-children-with-cerebral-palsy
#16
Akihiro Kawano, Taiichiro Yanagizono, Ichiro Kadouchi, Tetsuya Umezaki, Etsuo Chosa
BACKGROUND: Botulinum toxin A treatment involves injecting botulinum toxin A to relax muscle spasticity. Using ultrasonography, this study examined changes in the muscle architecture before and after treatment to evaluate the influence of botulinum toxin A injection on muscles. METHODS: The participants included 18 children (mean age, 6.2 years) with cerebral palsy who were treated with botulinum toxin A for lower extremity spasticity and 27 healthy children (mean age, 6...
November 13, 2017: Journal of Orthopaedic Science: Official Journal of the Japanese Orthopaedic Association
https://www.readbyqxmd.com/read/29145580/effect-of-botulinum-toxin-a-on-muscle-healing-and-its-implications-in-aesthetic-and-reconstructive-surgery
#17
Eldad Silberstein, Ehud Maor, Oleg Sukmanov, Alexander Bogdanov Berezovsky, Yaron Shoham, Yuval Krieger
Background: Muscle activity contributes to the enhancement of facial aging deformity, blepharospasm, cerebral palsy spasticity, trismus, torticollis, and other conditions. Myotomy of the involved muscles in order to reduce the deformity has variable success rates due to muscle healing and regeneration of activity. Objectives: The goal of this study was to investigate whether blocking striated muscle activity with Botulinum toxin (BtxA) during the healing time after myotomy alters the healing process and reduces long-term muscle activity...
November 14, 2017: Aesthetic Surgery Journal
https://www.readbyqxmd.com/read/29126361/a-survey-of-the-current-practice-of-intramuscular-botulinum-toxin-injections-for-hemiplegic-shoulder-pain-in-the-uk
#18
Richard J Holmes, Louise A Connell
PURPOSE: To describe the current UK practice for the use of intramuscular Botulinum Toxin type A injections to treat hemiplegic shoulder pain. METHOD: A UK-based cross-sectional study using an online survey. Participants (n = 68) were medical and non-medical practitioners recruited via the membership of the British Society for Rehabilitation Medicine and the British Neurotoxin Network. Data was analysed using descriptive statistics and content analysis. RESULTS: The majority of respondents would consider Botulinum Toxin type A for hemiplegic shoulder pain (86...
November 10, 2017: Disability and Rehabilitation
https://www.readbyqxmd.com/read/29116410/botulinum-toxin-therapy-in-patients-with-oral-anticoagulation-is-it-safe
#19
Christoph Schrader, Markus Ebke, Fereshte Adib Saberi, Dirk Dressler
When used therapeutically, botulinum toxin (BT) has to be injected into its target tissues. All manufacturers warn not to do so in patients with oral anticoagulation to avoid haematoma. We wanted to study the haematoma frequency (HF) in patients with anticoagulation receiving BT therapy. 32 patients (16 females, 16 males, age 69.3 ± 10.0 years) with blepharospasm (n = 6), hemifacial spasm (n = 8), post-stroke spasticity (n = 16), and cervical dystonia (n = 2) received BT therapy (needle size 27G, post-injection tissue compression) whilst on anticoagulation (anticoagulation group, AG)...
November 7, 2017: Journal of Neural Transmission
https://www.readbyqxmd.com/read/29089990/therapeutic-efficacy-and-safety-of-various-botulinum-toxin-a-doses-and-concentrations-in-spastic-foot-after-stroke-a-randomized-controlled-trial
#20
Jiang Li, Ru Zhang, Bo-Li Cui, Yong-Xiang Zhang, Guang-Tao Bai, Si-Shan Gao, Wen-Jian Li
No recommended guidelines currently exist for the therapeutic concentration or dose of botulinum toxin type A (BTXA) injected into the muscle to treat limb spasticity. Therefore, in this randomized controlled trial, we explored the safety and efficacy of two concentrations and two doses of BTXA in the treatment of spastic foot after stroke to optimize this treatment in these patients. Eligible patients (n = 104) were randomized into four groups. The triceps surae and tibialis posterior on the affected side were injected with BTXA at one of two doses (200 U or 400 U) and two concentrations (50 U/mL or 100 U/mL)...
September 2017: Neural Regeneration Research
keyword
keyword
105160
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"